1834-27-1

Basic information

• Product Name: 6-chloro-4-methyl-2H-pyridazin-3-one
• Synonyms: 6-chloro-4-methyl-2H-pyridazin-3-one;3(2H)-Pyridazinone, 6-chloro-4-Methyl-;6-Chloro-4-Methylpyridazin-3(2H)-one;6-Chloro-3-hydroxy-4-methylpyridazine;6-Chloro-4-methylpyridazin-3-ol, 6-Chloro-3-hydroxy-4-methyl-1,2-diazine;3-chloro-5-methyl-1H-pyridazin-6-one
• CAS NO: 1834-27-1
• Molecular Formula: C₅H₅ClN₂O
• Molecular Weight: 144.56
• Mol File: 1834-27-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 149-151 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.45g/cm³
• Refractive Index: 1.608
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.84±0.60(Predicted)
• CAS DataBase Reference: 6-chloro-4-methyl-2H-pyridazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-4-methyl-2H-pyridazin-3-one(1834-27-1)
• EPA Substance Registry System: 6-chloro-4-methyl-2H-pyridazin-3-one(1834-27-1)

Safety Data

• Hazardous Substances Data: 1834-27-1(Hazardous Substances Data)

Usage

General Description

6-chloro-4-methyl-2H-pyridazin-3-one is a chemical compound with the molecular formula C5H5ClN2O. It is a heterocyclic organic compound that contains a pyridazine ring with a chloro and a methyl group attached to it. 6-chloro-4-methyl-2H-pyridazin-3-one is a white solid that is insoluble in water but soluble in organic solvents. It is commonly used in pharmaceutical research and development as an intermediate in the synthesis of various biologically active compounds. Additionally, it has been investigated for its potential use in the treatment of various diseases and disorders due to its pharmacological properties.

InChI:InChI=1/C5H5ClN2O/c1-3-2-4(6)7-8-5(3)9/h2H,1H3,(H,8,9)

Upstream product

• 89466-38-6 6-chloro-3-methoxy-4-methylpyridazine 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 616-02-4 citraconic acid anhydride 
• 5754-18-7 4-methyl-1,2-dihydropyridazine-3,6-dione 

Downstream Products

• 1395922-81-2 C₂₀H₂₂N₆O 
• 886208-65-7 Minozac 
• 1395922-86-7 C₂₀H₂₂N₆O 
• 1395922-85-6 C₂₀H₂₂N₆ 
• 1395922-84-5 C₁₉H₁₉FN₆ 
• 1395922-83-4 C₂₀H₁₉F₃N₆ 
• 1395922-82-3 C₁₉H₁₉FN₆ 
• 1114573-48-6 (S)-3-((S)-1-(4-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one 
• 1114563-58-4 6-chloro-2,4-dimethylpyridazin-3(2H)-one 

Relevant articles and documents

Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

The capsid of hepatitis B virus (HBV) plays a vital role in virus DNA replication. Targeting nucleocapsid function has been demonstrated as an effective approach for anti-HBV drug development. A high-throughput screening and mechanism study revealed the h

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS

The present invention discloses compounds according to Formula I, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6a, X, Cy1, Cy2, and the subscript n and m are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (SIP) receptor, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, inflammatory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering the compound of the invention.